The website entered a new stage of development with the creation of scientific illustrations, mechanism-of-action graphics, corporate packaging concepts, disease pathway diagrams, therapeutic area graphics, and a...

The THCA PURE™ product family was formally defined, establishing the foundation for future pharmaceutical formulations based on standardized THCA. The initial platform consists of THCA PURE™ Oral and the future THCA...

Development began on the official THCA Therapeutics website. The objective was to create a professional digital platform communicating the company's mission, scientific foundation, research strategy, therapeutic...

THCA Therapeutics adopted an asset-light biotechnology development model centered on collaboration with GMP-certified Contract Development and Manufacturing Organizations (CDMOs). This strategy enables scalable...

The scientific rationale supporting THCA Therapeutics was further expanded through literature review and evidence mapping. Mechanistic pathways involving PPARγ activation, NF-κB inhibition, oxidative stress...

The investor materials evolved into a comprehensive biotechnology presentation with dedicated sections covering disease burden, mechanism of action, competitive landscape, intellectual property strategy, regulatory...

The company broadened its outreach to leading universities, clinicians, cannabinoid researchers, biotechnology organizations, and investment groups across Europe and North America. Discussions focused on future...

Following correspondence with the National Center for Complementary and Integrative Health (NCCIH), work began on preparing a formal NIH-style Specific Aims document describing the proposed THCA research platform....

THCA Therapeutics initiated its first structured outreach to biotechnology investors, venture capital firms, family offices, accelerators, and strategic partners. This represented the first public step toward...

The pitch deck and business plan were significantly expanded to include the biological mechanisms underlying THCA's therapeutic rationale. New scientific content addressed PPARγ activation, NF-κB inhibition,...

The first professional investor presentation was created to communicate the company's scientific vision, therapeutic strategy, development roadmap, and long-term business model. This marked the beginning of...

Development of the THCA Therapeutics corporate identity began. The project included creation of the company logo, visual identity, typography, corporate colors, pharmaceutical design language, and overall brand...

The company's scientific direction was formally established with rheumatoid arthritis selected as the lead indication. This decision was based on the significant unmet medical need in autoimmune diseases and the...

After years of scientific exploration and concept development, work began on transforming the original idea into a structured biotechnology company. The long-term vision expanded beyond a single product toward...

THCA Therapeutics traces its origins back to 2016, when founder Farbod Parvin began exploring the therapeutic potential of tetrahydrocannabinolic acid (THCA). Personal observations and a growing interest in...